Selective histamine H3 antagonist acid addition salt and preparation method thereof
By preparing the acid addition salt form of histamine H3 receptor antagonist compound, its problems in physical and chemical stability and hygroscopicity are solved, and better drug composition development and therapeutic effects are achieved.
Patent Information
- Application Number
- CN202080040296.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-31
- Filing Date
- 2020-05-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing histamine H3 receptor antagonist compounds have shortcomings in physical and chemical stability and hygroscopicity, resulting in processing, storage and stability problems in industrial-scale production and drug development.
1-[4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethyl Compounds in acid addition salt forms such as dihydrobromic acid, sulfate, oxalate, monocitrate and dicitrate of ketones are optimized through the polymorphs and hydrates/solvates of these salts. Its physical and chemical stability reduces hygroscopicity.
These acid addition salt compounds in the form of acids exhibit better physical and chemical stability, reduce hygroscopicity, improve solubility, and make them more suitable for the development of pharmaceutical compositions and the treatment of modulating histamine H3 receptor-related diseases .
Smart Images

Figure CN113906016B_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to physically and chemically stable salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone, a selective histamine H3 receptor antagonist compound of formula (1),
[0002]
[0003] and / or its polymorphs and / or its hydrates / solvates, methods for preparing the same, pharmaceutical compositions comprising the same, and use for treating and / or preventing conditions requiring modulation of histamine H3 receptors (e.g., Alzheimer's disease, obesity, schizophrenia, myocardial ischemia, migraine, autism spectrum disorders). Background of the Invention
[0005] Histamine H3 receptor antagonists are being extensively studied with the goal of producing drugs that can treat various diseases, such as Alzheimer's disease, obesity, schizophrenia, myocardial ischemia, migraine, nasal congestion, etc. (Leurs et al., Nat. Rev. Drug. Disc. 2005, 4(2):107-120; Berlin et al., J. Med. Chem. 2011, 54(1):26-53). Many compounds have shown promising preclinical results and have entered the clinical stage for diseases such as excessive daytime sleepiness (EDS) associated with Parkinson's disease, obstructive sleep apnea, epilepsy, schizophrenia, dementia, and attention deficit hyperactivity disorder (Kuhne et al., Exp. Opin. Inv. Drugs 2011, 20(12):1629-1648). It has been suggested that histamine H3 receptor antagonists / inverse agonists may also be suitable for the pharmacotherapeutic treatment of sleep disorders (Barbier and Bradbury, CNS Neurol. Disord. Drug Targets 2007, 6(1):31-43), but to date, only one histamine H3 receptor antagonist, pitolisant (Wakix brand), has received marketing authorization for the treatment of narcolepsy with or without cataplexy in adults (Kollb-Sielecka et al., Sleep Med. 2017, 33:125-129).
[0006] WO 2014 / 136075 describes the synthesis of chemically modifiable, selective, drug-like H3 antagonists and inverse agonists. The preparation and characterization of such phenoxypiperidine derivative compounds are disclosed, which bind to H3 receptors with high affinity and selectivity and are drug-like.
[0007] Among the compounds disclosed in WO 2014 / 136075, the hydrochloride salt of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone of formula (1) is highlighted. In the preparation of the compound described in Example 11, the starting material is 4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidine dihydrochloride. After the base is released, the reaction mixture is treated with acetyl chloride in dichloromethane. After aqueous extraction workup of the reaction mixture, the dehydrated dichloromethane solution of the base of formula (1) is evaporated. To a dichloromethane solution of the crude product is added an excess of hydrochloric acid in ethyl acetate. The precipitate was filtered off with ethyl acetate and washed with diethyl ether to give a crystalline product, ie, 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone hydrochloride.
[0008] A general requirement for active ingredients in the development of pharmaceutical compositions is that the active ingredient possess appropriate physical, physicochemical, and chemical parameters. Examples of such parameters include solubility, particularly water solubility. Another important characteristic to consider in industrial-scale production is ease of handling and good isolation, which are extremely important for the economic efficiency of the manufacturing process. Another important aspect is that the solid form of the active ingredient possesses appropriate physical and chemical stability, for example, it is non-hygroscopic and does not significantly degrade. In addition, different polymorphs of a given salt may have different solid phase characteristics, physical and chemical stability.
[0009] From the perspective of drug development, the water binding tendency and hygroscopicity (absorption capacity) of a substance are crucial because ambient humidity represents a significant interaction in addition to temperature. The hygroscopicity of an active ingredient can affect the handling, storage, stability, formulation, and many other properties of the substance. Several methods and approaches are available to characterize the hygroscopicity of active ingredients and to classify the hygroscopicity, which has been summarized in detail by Newman et al. (Newman et al., J. Pharm. Sci. 2007, 97(3): 1047-1059). Generally, the literature uses the categories of non-hygroscopic, slightly hygroscopic, moderately hygroscopic, extremely hygroscopic, and deliquescent, while the pharmacopoeia (European Pharmacopeia 9.0, Monographs 5.11 Character Section) uses the categories of less hygroscopic, hygroscopic, highly hygroscopic, and deliquescent, which are based on the weight gain over a given time at a given temperature and relative humidity under test conditions. There are static and dynamic measurement methods for studying hygroscopicity. Among dynamic measurements, dynamic vapor sorption (DVS) analysis is a technique commonly used in the pharmaceutical industry, which typically measures the mass change of a substance (adsorption and desorption curves) as a function of relative humidity under isothermal conditions, from which the nature, mechanism and phase transition of the adsorption process can be inferred.
[0010] For testing the hygroscopicity of active substances, it is particularly important to determine whether the substance is easily deliquescent, that is, what is the point at which the solid material is in a dissolved state when interacting with the ambient humidity (Mauer et al., Pharm. Dev. Techn. 2010, 15 (6): 582-594). When the relative humidity (RH) reaches or exceeds the critical relative humidity (CRH), the substance will deliquesce, and a thin film equivalent to a saturated solution of the substance is formed on the surface of the solid substance. By further increasing the humidity, the substance continues to absorb water, resulting in a sharp increase in weight due to the complete dissolution of the substance material and the dilution of the resulting solution. Even slight surface deliquescence of the substance may have a significant effect on the chemical stability of the compound, because such a microenvironment may occur in the case of compounds with acidic or alkaline characteristics, leading to degradation of compounds sensitive to acid or alkali. The deliquescence and strong hygroscopicity of crystalline drugs are generally due to their good solubility.
[0011] The critical relative humidity can be determined gravimetrically, for example using DVS, where the relative humidity is varied in appropriately chosen steps and for a period of time sufficient for the onset of quasi-equilibrium. After reaching the critical relative humidity, the adsorption curve exhibits a more or less sharp change in slope, which is usually followed by a monotonic rise and a significant increase in mass, the extent of which and the shape of the adsorption curve are likely to be independent of the formation of the hydrate form. Summary of the Invention
[0012] The base form of the salt of the present invention, 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone of formula (1) could not be isolated in a crystalline form but was isolated as an oil.
[0013] The aim is to obtain a solid form (salt and / or polymorph) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone having suitable properties in the above-mentioned aspects, exhibiting sufficient physical and chemical stability, being slightly hygroscopic, being non-deliquescent, thereby facilitating separation, being better handled and having excellent solubility.
[0014] It has been discovered that during the preparation of the crystalline form of the hydrochloride acid addition salt of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base, two crystalline polymorphs (Form A and Form B) of the monohydrochloride stoichiometry can be produced. In addition, in addition to the monohydrochloride salt, a crystalline dihydrochloride salt of the compound can also be produced.
[0015] Surprisingly, it has been discovered that the novel dihydrobromide, sulfate, oxalate, monocitrate, and dicitrate salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone have superior properties compared to the monohydrochloride and dihydrochloride salts. They are less hygroscopic, easier to separate, have improved physical and chemical stability, and possess excellent solubility. All of these beneficial properties of the novel dihydrobromide, sulfate, oxalate, monocitrate, and dicitrate salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone make them suitable for the development of pharmaceutical compositions for the treatment of diseases targeted by selective modulation of the H3 receptor.
[0016] The present invention relates to dihydrobromide, sulfate, oxalate, monocitrate and dicitrate of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone, and / or its polymorphs and / or hydrates / solvates, methods for preparing the same, pharmaceutical compositions containing the same, and use thereof in the treatment and / or prevention of diseases requiring modulation of histamine H3 receptors (e.g., Alzheimer's disease, obesity, schizophrenia, myocardial ischemia, migraine, autism spectrum disorders).
[0017] BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride Form A (Example 6).
[0019] Figure 2 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-Methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride Form A (Example 6).
[0020] Figure 3 X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride Form B (Example 7).
[0021] Figure 4 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride Form B (Example 7).
[0022] Figure 5 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride Form B (Example 7).
[0023] Figure 6 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-Methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride Form B (Example 7).
[0024] Figure 7 X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride (Example 2).
[0025] Figure 8 Thermogravimetric (TG) curve of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride (Example 2).
[0026] Figure 9Differential Scanning Calorimetry (DSC) thermogram of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride (Example 2).
[0027] Figure 10 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride (Example 2).
[0028] Figure 11 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride (Example 2).
[0029] Figure 12 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride (Example 2).
[0030] Hiba! A hivatkozási forrás nem található. Dynamic vapor sorption curves of the tested salts at 25°C (relative weight change % - relative humidity %) (a) deliquescent salt (b) non-deliquescent salt.
[0031] Figure 15 X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate salt Form A (Example 17).
[0032] Figure 16 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate Form A (Example 17).
[0033] Figure 17 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate Form A (Example 17).
[0034] Figure 18X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate salt Form B (Example 18).
[0035] Figure 19 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate Form B (Example 18).
[0036] Figure 20 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate Form B (Example 18).
[0037] Figure 21 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate (Example 17).
[0038] Figure 22 X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate (Example 20).
[0039] Figure 23 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate (Example 20).
[0040] Figure 24 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate (Example 20).
[0041] Figure 25 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate (Example 20).
[0042] Figure 26X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide (Example 9).
[0043] Figure 27 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide (Example 9).
[0044] Figure 28 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide (Example 9).
[0045] Figure 29 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide (Example 9).
[0046] Figure 30 X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate (Example 10).
[0047] Figure 31 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate (Example 10).
[0048] Figure 32 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate (Example 10).
[0049] Figure 33 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate (Example 10).
[0050] Figure 34X-ray powder diffraction (XRPD) pattern of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate (Example 13).
[0051] Figure 35 Infrared spectrum (IR) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate (Example 13).
[0052] Figure 36 Raman spectrum of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate (Example 13).
[0053] Figure 37 Dynamic Vapor Sorption (DVS) Isotherm of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate (Example 13).
[0054] Detailed Description of the Invention
[0055] The base form of the salt of the present invention, 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone of formula (1), cannot be isolated in crystalline form but is isolated in the form of an oil. The base can be obtained by evaporating a dichloromethane solution of the product obtained or by releasing the base after isolating the hydrochloride salt in a manner obvious to those skilled in the art according to the procedure described in Example 11 of WO 2014 / 136075.
[0056] The hydrochloric acid addition salt of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone base (Example 1) was prepared in crystalline form (Examples 2 to 8). Two crystalline polymorphs (Form A and Form B) of this salt characterized by the monohydrochloride stoichiometry have been found (Examples 4 to 8), of which the X-ray powder diffraction (XRPD) patterns, infrared (IR) and Raman spectra, and dynamic vapor sorption (DVS) isotherms are shown in Figure 2. Figures 1 to 6 As shown. Both monohydrochloride polymorphs (Form A and Form B) are highly hygroscopic and prone to deliquesce. According to DVS analysis at 25 ° C, Form A has a relative humidity of more than 40%, and Form B still has a relative humidity of more than 30%, resulting in a continuous high weight gain during the adsorption process due to deliquesce of the material.
[0057] In further experiments, it was found that in addition to the monohydrochloride, a crystalline dihydrochloride (diHCl) of the compound could also be produced (Examples 2 and 3), wherein the X-ray powder diffraction (XRPD) pattern, thermogravimetric (TG) curve, differential scanning calorimetry (DSC) thermogram, infrared (IR) and Raman spectra, and dynamic vapor sorption (DVS) isotherm diagram are as follows: Figures 7 to 12 As shown. The compound 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone contains a strongly basic center (pyrrolidine nitrogen) that is able to form a stoichiometric salt with equimolar hydrochloric acid. Therefore, considering the acid / base properties of the compound, it is expected that the stoichiometric dihydrochloride will not be formed. According to TG and DSC analysis, the second molar amount of hydrochloride is less strongly bound to the crystal lattice and appears as a volatile component. The thermal stability of this compound is very poor. According to TG analysis, the loss of volatile HCl can be observed at room temperature, but becomes strong at about 70 to 80 ° C ( Figure 8 In parallel with this process, according to DSC and microscopic analysis, the sample began to melt from about 100 °C during the decomposition process ( Figure 9 ).
[0058] Another disadvantage of the dihydrochloride form is that it is very hygroscopic. According to DVS (dynamic vapor sorption) analysis at 25°C, a significant monotonic weight increase is observed on the sorption curve above 60% relative humidity, indicating deliquesce of the material ( Figure 12 ).
[0059] The hygroscopic nature of the mono- and dihydrochloride salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone presents numerous challenges in pharmaceutical development, handling, storage, stability, and formulation of the compounds. The hydrochloride salt has been observed to readily deliquesce under isolation conditions, thus presenting problems with its filtration and handling. The substance's tendency to degrade is also clearly related to its hygroscopicity, with deacetylation potentially occurring upon exposure to acid in the presence of moisture.
[0060] Therefore, there is a need to prepare salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone that are less hygroscopic, easier to handle, and more physically and chemically stable than the monohydrochloride and dihydrochloride salts.
[0061] In our experiments, the dihydrobromide salt of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone (Example 9), the sulfate salt (
[0062] Examples 10 to 12), oxalate (Examples 13 and 14), monocitrate (Examples 15 to 18) and dicitrate (Examples 19 to 22), which are more preferred than the mono- and dihydrochloride salts because they are less hygroscopic (Table 1), are therefore easier to separate and handle, and their stability is more favorable (Table 2).
[0063] X-ray powder diffraction, IR and Raman data suitable for characterizing the polymorphic form of the crystalline salt of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone are shown in Tables 3 to 5.
[0064] Thus, the present invention relates to pharmaceutically acceptable, less hygroscopic acid addition salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone, which can be formed with organic or inorganic acids and / or polymorphs thereof and / or hydrates / solvates thereof. Examples of acid addition salts that can be formed with such organic or inorganic acids include salts derived from hydrobromic acid, sulfuric acid, oxalic acid or citric acid.
[0065] Preferably, the present invention relates to the dihydrobromide, sulfate, oxalate, monocitrate and dicitrate salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone and / or its polymorphs and / or its hydrates / solvates.
[0066] The present invention relates to the preparation of pharmaceutically acceptable, less hygroscopic acid addition salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone, which can be formed with organic or inorganic acids, preferably its dihydrobromide, sulfate, oxalate, monocitrate and dicitrate salts, and / or its polymorphs and / or its hydrates / solvates.
[0067] The present invention also relates to 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide, sulfate oxalate, monocitrate and biscitrate salts for use in the treatment and / or prevention of conditions requiring modulation of histamine H3 receptors.
[0068] The present invention also relates to the use of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone salt in the preparation of pharmaceutical compositions.
[0069] The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of dihydrobromide, sulfate, oxalate, monocitrate and dicitrate salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone and a pharmaceutically acceptable excipient.
[0070] The present invention also relates to the use of the pharmaceutical composition of the previous paragraph for the treatment and / or prevention of conditions requiring modulation of histamine H3 receptors, preferably for the treatment and / or prevention of autism spectrum disorders.
[0071] For example, the preparation of salts from bases can be carried out by dissolving the 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base in a suitable solvent or solvent mixture and then adding an acid or a salt thereof, said salt being formed from a base weaker than 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone, or a solution thereof. In addition, the 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base can be prepared from its salt by, after liberation of the base, without isolating the base, and after appropriate isolation and / or solvent exchange, by adding an acid to form the desired salt. If necessary, the reaction mixture is concentrated and the precipitated product is isolated by filtration at room temperature or after cooling and then, if necessary, dried at a suitable temperature. If necessary, the resulting salt is crystallized from its solution by adding a suitable antisolvent at room temperature or after reflux and the precipitated product is isolated by filtration and then, if necessary, dried at a suitable temperature.
[0072] The salts of the present invention can be isolated very well and, due to the high purity achieved by the process, are particularly valuable for pharmaceutical applications. In the practice of the present invention, the monocitrate and dicitrate salts are particularly preferred for use in preparing pharmaceutical compositions, whereby the highest quality and most stable products are obtained in excellent yields. The monocitrate and dicitrate salts are poorly hygroscopic, do not exhibit deliquescence, are physically and chemically stable, and have excellent solubility.
[0073] Both citrate salts have higher melting points than the dihydrochloride salt. In the case of the monocitrate salt, this is approximately 15°C, while in the case of the dicitrate salt, an increase in melting point of approximately 30°C can be observed, indicating greater stability and greater convenience for the preparation of pharmaceutical compositions. The monocitrate salt is stable in the monohydrate form (monocitrate form A) under normal laboratory conditions, but upon increasing the temperature from room temperature to approximately 70 to 90°C, it loses its weakly bound structural water and converts to the anhydrate form (monocitrate form B). Upon interaction with ambient humidity, dried samples also absorb their stoichiometric water content relatively quickly. The dicitrate salt is stable in its anhydrate form, does not convert to the hydrate form, and has a sufficiently high melting point for development purposes.
[0074] Dynamic vapor sorption curves for the investigated salts of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone measured at 25°C are plotted in Error! Reference source not found. , which represents the relative weight change (~percent change, relative to the weight at 0% relative humidity) as a function of relative humidity (RH%).
[0075] In the monohydrochloride type A ( Figure 2 ), about 3% of water is bound until 40% RH and then liquefies at higher humidity (95% RH - relative weight change: 97%).
[0076] On the adsorption curve of monohydrochloride type B ( Figure 6 ), only 0.3% of water is bound until 30% RH, presumably by surface adsorption, and then liquefies at higher humidities (95% RH - relative weight change: 61%).
[0077] On the adsorption curve of dihydrochloride ( Figure 12 ), about 0.7% of water is bound relative to the dry substance until 60% RH, and then liquefies at higher humidities (already showing a relative weight gain of 17% at 70% RH and a relative weight change of 63% at 90% RH).
[0078] In the case of the DVS measurement of the dihydrochloride, unlike the general method description, no measurements were performed in the measurement cycles at 5% and 95% relative humidity, but this difference did not significantly affect the determination of the onset of deliquescence (see below).
[0079] On the adsorption curve of dihydrobromide ( Figure 29 ), it absorbs about 6% of moisture until 70% RH and then liquefies at higher humidity (95% RH - relative weight change: 90%).
[0080] On the sulfate adsorption curve ( Figure 33 ), about 5% of water is bound up to 80% RH, and then liquefies at higher humidity (95% RH - relative weight change: 53%).
[0081] On the adsorption curve of oxalate ( Figure 37 ), a relative weight increase of approximately 4.7% relative to the dry weight was observed in the 10-50% RH range, which appeared to be constant until approximately 70% RH. This weight change indicates the formation of a hydrated form with a stoichiometry close to that of the monohydrate. Further water absorption began above 80% RH, but under the conditions tested, the oxalate did not even show deliquescence above 90% RH. During the desorption cycle between 20% and 70% RH, it stabilized at a relative weight of 7.1% to 7.3%, indicating the formation of a stoichiometry corresponding to that of the dihydrate form. Thus, the oxalate is stable in the form of a hydrate with a composition that varies depending on the humidity.
[0082] In the DVS curve of monocitrate ( Figure 21 ) on a 1.5% RH (1.5% RH) spherical ion exchanger (EDS) was used to separate the monohydrate (Form A) and anhydrate (Form B) forms of the sample. Relative to the dry state, above 30% RH, it absorbed 2.6-4.3% water, which is close to the theoretical value (3.2%) for monocitric acid monohydrate. The monohydrate form proved so stable that during desorption, Form A converted to Form B only below 10% RH. Even above 90% RH, the monocitrate salt showed no deliquescence.
[0083] On the adsorption curve of dicitrate ( Figure 25 ), 3.2% water bound up to 80% RH, 6.8% water bound up to 90% RH, showed no deliquescence above 90% RH, and its weight decreased reversibly during the desorption stage.
[0084] The generally observed hygroscopicity of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone salts is particularly relevant to their good solubility. In simulated gastric fluid (SGF without pepsin, pH 1.3), the solubility of the dihydrochloride salt is greater than 59 mM, the solubility of the monocitrate salt is greater than 44 mM, and the solubility of the dicitrate salt is 469 mM.
[0085] The deliquescent tendency of each salt is characterized by the critical relative humidity (CRH) value (Table 1), which is determined according to the following, using DVS analysis at 25°C isotherm conditions, based on the adsorption curve measured according to the following measurement parameter settings.
[0086] The derivative of the adsorption curve was formed between 10% and 90% RH by determining the difference in relative weight change for a 10% RH change:
[0087] Δm=m2-m1
[0088] where m1 and m2 are the quasi-equilibrium relative mass changes (~percentage change in weight relative to the weight at 0% relative humidity) for a given percentage of relative humidity for the adsorption curves RH1 and RH2, and
[0089] ΔRH=RH2-RH1=10.
[0090] If Δm / ΔRH ≥ 0.5 for a given adsorption step, then RH1 is considered the critical relative humidity (CRH) value, indicating the end point of the physical stability of the substance. The value thus determined matches well with the onset of a significant monotonic weight gain visually observed on the sorption curve. Above the critical relative humidity value, it is the deliquescence process of the substance that determines the weight gain observed on the adsorption curve.
[0091] Table 1. Characterization of the deliquescent properties of the tested salts based on critical relative humidity (CRH) and Δm / ΔRH values from DVS analysis at 25 °C.
[0092]
[0093]
[0094] Compared to the monohydrochloride salt, it can be determined that the diHBr and sulfate salts begin to exhibit deliquesce at a significantly higher critical relative humidity, which indicates a reduced hygroscopic tendency associated with their greater physical stability. Surprisingly, the oxalate, monocitrate, and dicitrate salts do not deliquesce under the DVS analysis conditions and are the most physically stable salts.
[0095] Increased stability to ambient humidity is beneficial to the long-term physical and chemical stability of the active ingredient. A relationship between reduced hygroscopicity and the associated increased chemical stability is shown in the most preferred citrate salt compared to the dihydrochloride salt.
[0096] Table 2 shows the HPLC purity test results of the 10-day solid stress stability study of the dihydrochloride, monocitrate, and dicitrate salts. As can be seen from the results, the dihydrochloride salt degrades slightly under heat, while it degrades significantly under the combined effects of heat and humidity. In contrast, the monocitrate and dicitrate salts are stable under these conditions and are significantly more favorable.
[0097] Table 2. HPLC purity test results for the 10-day solid stress stability study of the dihydrochloride, monocitrate, and dicitrate salts.
[0098]
[0099] Table 3. X-ray powder diffraction characteristics of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone crystalline salt and its polymorphs
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109] Table 4. Characteristic peaks measured in the infrared spectra of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone crystalline salt and its polymorphs [cm -1 ].
[0110]
[0111] Table 5. Characteristic peaks measured in Raman spectra of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone crystalline salt and its polymorphs [cm -1 ].
[0112]
[0113] For solid phase analysis studies, the following experimental conditions were used:
[0114] FT-IR spectrum measurement parameters:
[0115]
[0116] FT-Raman spectroscopy measurement parameters:
[0117]
[0118] X-ray powder diffraction measurement parameters:
[0119]
[0120]
[0121] TG measurement parameters:
[0122] DSC measurement parameters:
[0123] DVS measurement parameters:
[0124]
[0125]
[0126] Pharmaceutical composition
[0127] The salts of the present invention can be administered in any pharmaceutically acceptable manner suitable for the formulation of pharmaceutical compositions, for example, orally, parenterally, buccally, sublingually, nasally, rectally or transdermally. The therapeutically effective dose is 0.01 to 40 mg / day.
[0128] The following formulation examples illustrate the pharmaceutical compositions of the present invention. However, the present invention is not limited to these compositions.
[0129] A) Solid Oral Dosage Forms
[0130] tablet
[0131]
[0132] B) Parenteral Dosage Forms
[0133] intravenous injection
[0134]
[0135]
[0136] C) Other dosage forms
[0137] suppositories
[0138] Example
[0139] The present invention is illustrated by the following reference and working examples, without however limiting the scope of the invention.
[0140] Reference Examples
[0141] Example 1
[0142] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone
[0143] 40 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone hydrochloride, prepared according to Example 11 of WO 2014 / 136075, was dissolved in 480 mL of dichloromethane at 0-5° C., and 168 mL of 1 M aqueous NaOH solution was added. After stirring for 10 minutes, the aqueous and organic phases were separated, and the organic phase was washed twice with 120 mL of deionized water, dried over 25 g of sodium sulfate, and filtered. The solution was concentrated in vacuo to an oil. Evaporation residue: 32.8 g of oil.
[0144] Example 2
[0145] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride
[0146] 2.0 g (5.55 mmol) of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone was dissolved in 20 mL of acetone at room temperature. The reaction mixture was cooled to 0 to 5° C. and 0.8 mL of ≥37% hydrochloric acid solution was added dropwise. After stirring at 0 to 5° C. for 30 minutes, the crystals were filtered, covered with 1.5 mL of cold acetone, and dried at room temperature. White crystalline substance. Yield: 1.7 g.
[0147] Example 3
[0148] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride
[0149] At room temperature, 0.548 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone was dissolved in 1.1 mL of isopropanol. 0.391 g of 30% isopropanol hydrochloric acid was added dropwise to the base solution at room temperature. The precipitated slurry was filtered and then dried under vacuum at 40°C under nitrogen for 2 hours. Yield: 0.42 g.
[0150] Example 4
[0151] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monohydrochloride Form A
[0152] 11.831 mg of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride were weighed into a platinum pot and thermally treated in a TA Instruments TGA Q50 instrument according to the following program until 1 mol of HCl was eliminated:
[0153] 1. Heat to 90°C at a heating rate of 10°C / min
[0154] 2. Maintain at 90°C for 103.7 minutes
[0155] 3. Heat to 95°C at a heating rate of 10°C / min
[0156] 4. Maintain at 95°C for 12.9 minutes
[0157] 5. Heat to 100°C at a heating rate of 10°C / min
[0158] 6. Maintain at 100°C for 180 minutes.
[0159] Example 5
[0160] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monohydrochloride Form A
[0161] 0.4mL sodium bicarbonate aqueous solution (97.5mg NaHCO / 1mL H O) is added to 0.2g 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride. In the case of using equimolar base, 1mol HCl is released during the effervescent process of the solution. 1mL 1,4-dioxane is added to the solution and an oil is obtained after evaporation. 20 to 30mg of oil are mixed with 0.5mL methyl ethyl ketone, filtered and precipitated with 0.5mL diisopropyl ether to obtain an oil. By the 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone monohydrochloride seed crystals obtained by the heat treatment of Example 4. After crystallization, the product is filtered and dried at room temperature. Yield: 27mg.
[0162] Example 6
[0163] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monohydrochloride Form A
[0164] 0.1 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride was dissolved in 0.2 mL of deionized water and 0.2 mL of an aqueous sodium bicarbonate solution (97.5 mg NaHCO3 / 1 mL H2O) was added. The resulting solution was concentrated at 50°C and 70 mbar, then dissolved in 5 mL of methyl ethyl ketone, filtered, and washed with 1 mL of methyl ethyl ketone. 11.5 mL of diisopropyl ether was added to the solution and seeded with the product of Example 4. An oily precipitate was observed. The solution was concentrated to dryness, and the "residue" was dissolved in 1 mL of dimethylformamide, 15 mL of methyl tert-butyl ether was added, and then seeded with the product of Example 5. The next day, the precipitated crystalline product was isolated by filtration. Yield: 25 mg.
[0165] Example 7
[0166] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monohydrochloride type B
[0167] At room temperature, 2.0 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base was dissolved in 20 mL of acetone. The reaction mixture was cooled to 0 to 5°C and 0.4 mL of ≥37% hydrochloric acid solution was added dropwise. After stirring at 0 to 5°C for 30 minutes, it was concentrated in vacuo in a 40°C water bath to constant weight. Then, 30 mL of toluene was evaporated twice. A white crystalline substance was obtained. Yield: 1.5 g.
[0168] Example 8
[0169] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monohydrochloride type B
[0170] 0.548 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base was dissolved in 0.55 mL of methyl tert-butyl ether at room temperature. 0.18 g of 30% isopropyl hydrochloride was slowly added dropwise to the base solution at room temperature. The initially biphasic mixture became miscible under stirring and then transformed into a thick crystalline suspension. The precipitated suspension was filtered and dried in vacuo at 40° C. under nitrogen for 2 hours. Yield: 0.33 g.
[0171] Working Examples
[0172] Example 9
[0173] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide
[0174] At room temperature, 0.53 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base was dissolved in 5 mL of ethyl acetate, and then 0.8 mL of acetic acid saturated with hydrobromic acid was added to form the salt. After filtration, the product was washed twice with 1 mL of acetic acid saturated with hydrobromic acid. The dried product weighed 0.65 g.
[0175] Example 10
[0176] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate
[0177] At room temperature, 0.1 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was dissolved in 9 mL of acetone, and then 0.125 mL of 20.4% H2SO4 solution was slowly added dropwise. The resulting solution first turned milky white, then a crystalline suspension was obtained, which was stirred at room temperature for 2 hours. The product was filtered and washed twice with 0.5 mL of acetone. It was dried in vacuo at 40°C under nitrogen for 2 hours. Yield: 0.08 g.
[0178] Example 11
[0179] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate
[0180] 0.99 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was dissolved in 20 mL of acetone, and then 1.3 mL of 18.4% H2SO4 solution was added. The mixture was seeded with the product of Example 10 (0.05 mL of water was added). The product was precipitated with 20 mL of acetone, stirred for half an hour, filtered, washed and dried at 40°C under nitrogen. Yield: 0.814 g. Melting point of the product (based on DSC peak): 79.5°C.
[0181] Example 12
[0182] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate
[0183] 1.008 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was mixed with 0.935 mL of 3M HSO and stirred for 15 minutes. 20 mL of acetone was added to seed with the product of Example 11 and then stirred at room temperature overnight. The mixture was filtered and dried at 40° C. under nitrogen to constant weight. Yield: 0.895 g. The melting point of the product (based on DSC peak) was 79.3° C.
[0184] Example 13
[0185] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Oxalate
[0186] At room temperature, 0.1 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was dissolved in 0.1 mL of acetone and a solution of 0.055 g of oxalic acid in 0.5 mL of acetone was added. The product was precipitated with 0.3 mL of ethyl acetate. The mixture was filtered and then dried under nitrogen to constant weight. Yield: 128 mg. The melting point of the product (based on DSC peak): 54.2° C.
[0187] Example 14
[0188] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Oxalate
[0189] 0.5 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was dissolved in 0.5 mL of acetone, followed by a solution of 0.275 g of oxalic acid in 1.5 mL of acetone and 0.05 mL of water. The precipitated material was filtered and then stirred in a mixture of 0.05 mL of water and 2.75 mL of acetone in the presence of 0.1755 g of oxalic acid. The resulting product was filtered and dried. Yield: 392 mg.
[0190] Example 15
[0191] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monocitrate Type A
[0192] To 0.13 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was added 0.081 g of citric acid monohydrate with stirring at room temperature. 0.5 mL of acetone was added and stirred overnight. On the second day, another 1 mL of acetone was added, and the mixture was stirred for another 30 minutes, then filtered and washed with 0.5 mL of acetone. The resulting sample was dried in vacuo at 25° C. under nitrogen. Yield: 0.163 g.
[0193] Example 16
[0194] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monocitrate Type A
[0195] To 0.513 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was added a solution of 0.315 g of citric acid monohydrate in 5 mL of acetone at room temperature. The solution was seeded with the product from Example 15. After stirring for two hours, an additional 2 mL of acetone was added and stirred over the weekend. The mixture was filtered and washed with 5 mL of acetone. The resulting crystalline material was dried in vacuo at 25° C. under nitrogen. Yield: 0.63 g. Karl Fischer water content: 3.1%.
[0196] Example 17
[0197] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monocitrate Type A
[0198] 1.020 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was weighed into a 100 mL reactor and stirred with 15 mL of acetone at room temperature. To this solution was added 15 mL of citric acid monohydrate solution (0.872 g of citric acid monohydrate dissolved in 20 mL of acetone) at room temperature. Simultaneously, the solution was seeded with a suspension of the monocitrate salt prepared in Example 16 (0.0767 g suspended in 0.5 mL of acetone).
[0199] The resulting suspension was stirred at room temperature for 1 hour, after which the precipitated salt was filtered and washed with 10 mL of acetone. The resulting crystalline material was dried at 25° C. under nitrogen. Yield: 1.385 g. Melting point of the product (DSC onset): 114.3° C. Karl Fischer water content: 3.5%.
[0200] Example 18
[0201] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Monocitrate Type B
[0202] The monocitrate salt Form A of Example 17 was dried to constant weight at 70 to 90°C under nitrogen.
[0203] Example 19
[0204] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Dicitrate
[0205] 0.5 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil was dissolved in 1 mL of acetone, and a solution of 0.962 g of citric acid monohydrate in 4 mL of acetone was added. After stirring at reflux for 1 hour and 15 minutes, the mixture was cooled to room temperature, filtered, and washed with 10 mL of acetone. The resulting sample was dried overnight at 25°C under vacuum and nitrogen. Yield: 0.832 mg.
[0206] Example 20
[0207] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Dicitrate
[0208] 1.928 g of citric acid monohydrate was added to a 100 mL reactor and dissolved in 15 mL of acetone at room temperature. To this solution was added a suspension of the dicitrate salt prepared in Example 19 in acetone (0.1039 g / 0.5 mL). To this solution was added 15 mL of an acetone solution of the base (1.695 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base oil dissolved in 17.5 mL of acetone). The solution was stirred at room temperature for 1 hour, then filtered and washed with 10 mL of acetone. The resulting sample was dried at 25° C. under nitrogen for 1 day. Yield: 2.81 g. Melting point of the product (DSC onset): 133.1° C. Karl Fischer water content: 0.4%.
[0209] Example 21
[0210] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Dicitrate
[0211] 17.6 kg of dichloromethane are introduced into a reactor which is then inertized with nitrogen and the temperature is set to 0 to 5° C. 1.1 kg of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride are added, followed by a mixture of 5.7 kg of purified water and 0.19 kg of NaOH, while maintaining the temperature at 0 to 5° C. After a reaction time of 15 to 20 minutes, the organic phase is introduced into another reactor which is also inertized with nitrogen. 2200 ml of dichloromethane are added to the organic phase and, after stirring for 30 to 40 minutes, the organic phase is separated again. The following steps are repeated twice: 3300 ml of purified water are added to the organic phase and, after stirring for 30 to 40 minutes, the organic phase is separated again. A solution of 0.66 kg of NaCl in 2.6 L of purified water is added to the separated organic phase and, after stirring for 30 to 40 minutes, the organic phase is separated again. The organic phase was concentrated to the stirring limit (to 3-4 liters) at a maximum of 35° C. under a vacuum of 0.5 bar. This was repeated three times, 8.8 kg of acetone were added, and the liberated base was concentrated to the stirring limit (to 3-4 liters) at a maximum of 45° C. under a vacuum of 0.7 bar. 1.1 kg of citric acid monohydrate was dissolved in 7.0 kg of acetone, while maintaining the solution temperature at 20 to 25° C. To the resulting citric acid solution was added 5.0 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate seeds. To the resulting citric acid solution, a concentrated solution of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone base in acetone was added over 110 to 130 minutes, maintaining the temperature between 20 and 25°C. After the addition, the mixture was heated to 55-60°C and stirred at this temperature for 10 to 12 minutes and then cooled to 20 to 25°C for another 10 hours. At the end of the stirring time, the material was centrifuged and dried. Yield: 1.398 kg. Melting point of the product (DSC onset): 132.7°C.
[0212] Example 22
[0213] 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propyloxy}-phenoxy)-piperidin-1-yl]-ethanone Dicitrate
[0214] 70 g of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride was weighed and dissolved in 840 mL of dichloromethane at 0 to 5° C., followed by addition of a solution of 11.9 g of NaOH in 350 mL of deionized water. After stirring for 15 minutes, the mixture was separated and the aqueous phase was transferred to 140 mL of dichloromethane. The combined organic phases were extracted twice with 210 mL of deionized water and then with 210 mL of saturated brine. The solution was concentrated in vacuo to an oil (at a maximum of 35° C.). The mixture was diluted three times with 700 mL of acetone and evaporated. The evaporation residue was made up to 560 mL with acetone. A solution of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone in acetone was added over two hours to a solution of 64 g of anhydrous citric acid in 560 mL of acetone and 6 mL of water (20 to 25° C.), maintained at 20 to 25° C. After stirring at reflux for 15 minutes, the suspension was cooled back to room temperature and stirred for a further 2 hours. The precipitate was then filtered off, washed twice with 60 mL of acetone and dried in vacuo at 50° C. Yield: 101.6 g. Melting point of the product (DSC onset): 132.6° C.
Claims
1. Crystalline Form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate, characterized in that Based on dynamic vapor sorption (DVS) analysis at 25°C a.) shows deliquescence only above 70% relative humidity, i.e. the critical relative humidity (CRH) value indicating the onset of deliquescence determined within the 10% to 90% RH range of the adsorption curve is at least 70%; or b.) does not show deliquesce, i.e. is characterized by a value of 0.5 >∆m / ∆RH in the 10% to 90% RH range of the adsorption curve, where ∆m=m2-m1, corresponding to the difference between the quasi-equilibrium relative mass changes m2 and m1 for the relative humidity values RH2 and RH1, and where ∆RH=RH2-RH1=10; The characteristic reflections in its X-ray powder diffraction pattern exist in the following scattering angle value ranges: 9.4; 11.1; 13.5; 18.0; 19.5; 19.8; 21.5° ± 0.2° 2θ.
2. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to claim 1, characterized in that Its X-ray powder diffraction pattern corresponds to the X-ray powder diffraction pattern shown in FIG15 .
3. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to claim 1, characterized in that The absorption bands in its infrared spectrum exist in the following value ranges: 3466; 3011; 2962; 1731; 1618; 1594; 1507; 1217; 1043; 665 cm -1 ± 4 cm -1 .
4. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to claim 1, characterized in that The absorption bands in its Raman spectrum exist in the following value ranges: 3065; 2961; 2931; 1715; 1618; 1480; 1242; 1134; 859; 840; 722 cm -1 ± 4cm -1 .
5. Crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate, characterized in that Based on dynamic vapor sorption (DVS) analysis at 25°C a.) shows deliquescence only above 70% relative humidity, i.e. the critical relative humidity (CRH) value indicating the onset of deliquescence determined within the 10% to 90% RH range of the adsorption curve is at least 70%; or b.) does not show deliquesce, i.e. is characterized by a value of 0.5 > ∆m / ∆RH in the 10% to 90% RH range of the adsorption curve, where ∆m=m2-m1, corresponding to the difference between the quasi-equilibrium relative mass changes m2 and m1 for the relative humidity values RH2 and RH1, and where ∆RH=RH2-RH1=10; The characteristic reflections in its X-ray powder diffraction pattern exist in the following scattering angle value range: 9.5; 11.3; 13.4; 13.7; 14.0; 17.8; 19.1; 20.4; 22.3° ± 0.2° 2θ.
6. The crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to claim 5, characterized in that Its X-ray powder diffraction pattern corresponds to the X-ray powder diffraction pattern shown in FIG18 .
7. The crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to claim 5, characterized in that The absorption bands in its infrared spectrum exist in the following value ranges: 2962; 2872; 1732; 1637; 1595; 1508; 1217; 1068; 1043; 818 cm -1 ± 4 cm -1 .
8. The crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to claim 5, characterized in that The absorption bands in its Raman spectrum exist in the following value ranges: 3086; 2930; 2881; 1718; 1628; 1476; 1251; 857; 718 cm -1 ± 4 cm -1 .
9. Crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate, characterized in that Based on dynamic vapor sorption (DVS) analysis at 25°C a.) shows deliquescence only above 70% relative humidity, i.e. the critical relative humidity (CRH) value indicating the onset of deliquescence determined within the 10% to 90% RH range of the adsorption curve is at least 70%; or b.) does not show deliquesce, i.e. is characterized by a value of 0.5 >∆m / ∆RH in the 10% to 90% RH range of the adsorption curve, where ∆m=m2-m1, corresponding to the difference between the quasi-equilibrium relative mass changes m2 and m1 for the relative humidity values RH2 and RH1, and where ∆RH=RH2-RH1=10; The characteristic reflections in its X-ray powder diffraction pattern exist in the following scattering angle value range: 10.2; 12.0; 12.8; 14.1; 19.0; 19.3; 20.5; 22.8° ± 0.2° 2θ.
10. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to claim 9, characterized in that Its X-ray powder diffraction pattern corresponds to the X-ray powder diffraction pattern shown in FIG. 22 .
11. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to claim 9, characterized in that The absorption bands in its infrared spectrum exist in the following value ranges: 3523; 3038; 2521; 1727; 1687; 1587; 1507; 1216; 782; 661 cm -1 ± 4 cm -1 .
12. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to claim 9, characterized in that The absorption bands in its Raman spectrum exist in the following value ranges: 3070; 2971; 2933; 1611; 1489; 936; 854; 782; 720; 660 cm -1 ± 4 cm -1 .
13. Crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide, characterized in that Based on dynamic vapor sorption (DVS) analysis at 25°C a.) shows deliquescence only above 70% relative humidity, i.e. the critical relative humidity (CRH) value indicating the onset of deliquescence determined within the 10% to 90% RH range of the adsorption curve is at least 70%; or b.) does not show deliquesce, i.e. is characterized by a value of 0.5 >∆m / ∆RH in the 10% to 90% RH range of the adsorption curve, where ∆m=m2-m1, corresponding to the difference between the quasi-equilibrium relative mass changes m2 and m1 for the relative humidity values RH2 and RH1, and where ∆RH=RH2-RH1=10; The characteristic reflections in its X-ray powder diffraction pattern exist in the following scattering angle value ranges: 5.6; 11.3; 16.4; 16.7; 17.0; 24.7; 28.5° ± 0.2° 2θ.
14. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to claim 13, characterized in that Its X-ray powder diffraction pattern corresponds to the X-ray powder diffraction pattern shown in FIG. 26 .
15. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to claim 13, characterized in that The absorption bands in its infrared spectrum exist in the following value ranges: 3419; 2930; 2614; 1685; 1616; 1508; 1232; 817 cm -1 ± 4 cm -1 .
16. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to claim 13, characterized in that The absorption bands in its Raman spectrum exist in the following value ranges: 3072; 3022; 3045; 2935; 1613; 1265; 1164; 852 cm -1 ± 4 cm -1 .
17. Crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate, characterized in that Based on dynamic vapor sorption (DVS) analysis at 25°C a.) shows deliquescence only above 70% relative humidity, i.e. the critical relative humidity (CRH) value indicating the onset of deliquescence determined within the 10% to 90% RH range of the adsorption curve is at least 70%; or b.) does not show deliquesce, i.e. is characterized by a value of 0.5 >∆m / ∆RH in the 10% to 90% RH range of the adsorption curve, where ∆m=m2-m1, corresponding to the difference between the quasi-equilibrium relative mass changes m2 and m1 for the relative humidity values RH2 and RH1, and where ∆RH=RH2-RH1=10; The characteristic reflections in its X-ray powder diffraction pattern exist in the following scattering angle value range: 7.8; 11.7; 15.6; 18.0; 18.5; 19.6; 19.9; 22.9° ± 0.2° 2θ.
18. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to claim 17, characterized in that Its X-ray powder diffraction pattern corresponds to the X-ray powder diffraction pattern shown in FIG. 30 .
19. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to claim 17, characterized in that The absorption bands in its infrared spectrum exist in the following value ranges: 3389; 2955; 2615; 2513; 1590; 1507; 1220; 1044; 855; 591 cm -1 ± 4 cm -1 .
20. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to claim 17, characterized in that The absorption bands in its Raman spectrum exist in the following value ranges: 3076; 3059; 2935; 1613; 1584; 1453; 1257; 1053; 854; 723 cm -1 ± 4 cm -1 .
21. Crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate, characterized in that Based on dynamic vapor sorption (DVS) analysis at 25°C a.) shows deliquescence only above 70% relative humidity, i.e. the critical relative humidity (CRH) value indicating the onset of deliquescence determined within the 10% to 90% RH range of the adsorption curve is at least 70%; or b.) does not show deliquesce, i.e. is characterized by a value of 0.5 >∆m / ∆RH in the 10% to 90% RH range of the adsorption curve, where ∆m=m2-m1, corresponding to the difference between the quasi-equilibrium relative mass changes m2 and m1 for the relative humidity values RH2 and RH1, and where ∆RH=RH2-RH1=10; The characteristic reflections in its X-ray powder diffraction pattern exist in the following scattering angle value ranges: 8.5; 14.8; 15.4; 16.5; 17.4; 20.8; 22.5° ± 0.2° 2θ.
22. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to claim 21, characterized in that Its X-ray powder diffraction pattern corresponds to the X-ray powder diffraction pattern shown in FIG. 34 .
23. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to claim 21, characterized in that The absorption bands in its infrared spectrum exist in the following value ranges: 3431; 2513; 1987; 1706; 1693; 1507; 1220; 832; 722 cm -1 ± 4 cm -1 .
24. The crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to claim 21, characterized in that The absorption bands in its Raman spectrum exist in the following value ranges: 3077; 2935; 2883; 1611; 1477; 1443; 858; 842; 725 cm -1 ± 4 cm -1 .
25. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 10 to 15, A method for preparing the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to any one of claims 13 to 16, the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to any one of claims 17 to 20, or the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to any one of claims 21 to 24, characterized in that: The 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base is dissolved in a suitable solvent or solvent mixture, and then the acid or its salt, or a solution thereof, which is formed from a base weaker than 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone is added to the mixture, and then the precipitated product is separated by filtration at room temperature or after cooling, optionally increasing the concentration of the reaction mixture, or without increasing the concentration.
26. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 10 to 15, A method for preparing the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to any one of claims 13 to 16, the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to any one of claims 17 to 20, or the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to any one of claims 21 to 24, characterized in that: 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base is dissolved in a suitable solvent or solvent mixture, then to the mixture is added an acid or its salt, or a solution thereof, the salt being formed from a base weaker than 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone, followed by crystallization using a suitable antisolvent which is added to the solution thus obtained at room temperature or after cooling, and the precipitated product is isolated by filtration.
27. A method for preparing the crystalline Form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, the crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, or the crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12, which adopts the following method: (i) dissolving 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base in acetone; and (ii) The citrate salt is crystallized by adding a solution of citric acid in acetone to a solution of the base in acetone.
28. A method for preparing the crystalline Form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, the crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, or the crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12, which adopts the following method: (i) dissolving 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone base in acetone; and (ii) The citrate salt is crystallized by adding a solution of the base in acetone to a solution of citric acid in acetone.
29. A method for preparing the crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to claims 9-12, which adopts the following method: (i) starting from 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrochloride, releasing the base after solvent exchange in acetone and evaporating the solution; and (ii) The dicitrate salt is crystallized by adding a solution of the base in acetone to a solution of citric acid in acetone.
30. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12, and the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 13 to 15. 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to any one of claims 16, 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to any one of claims 17 to 20, or 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to any one of claims 21 to 24, for use in the treatment and / or prevention of conditions requiring histamine H3 receptor modulation.
31. The crystalline form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, the crystalline form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12, the crystalline form C of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 1 to 4, The invention relates to the use of crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to any one of claims 13 to 16, crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to any one of claims 17 to 20, or crystals of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to any one of claims 21 to 24 in the preparation of a pharmaceutical composition.
32. A pharmaceutical composition comprising a therapeutically effective amount of crystalline Form A of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 1 to 4, crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone monocitrate according to any one of claims 5 to 8, crystalline Form B of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dicitrate according to any one of claims 9 to 12. , a crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone dihydrobromide according to any one of claims 13 to 16, a crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone sulfate according to any one of claims 17 to 20, or a crystal of 1-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-1-yl]-propoxy}-phenoxy)-piperidin-1-yl]-ethanone oxalate according to any one of claims 21 to 24 and one or more pharmaceutically acceptable excipients.
33. Use of a pharmaceutical composition according to claim 32 for the preparation of a medicament for the treatment and / or prevention of conditions requiring histamine H3 receptor modulation.
